Cargando…
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refract...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256976/ https://www.ncbi.nlm.nih.gov/pubmed/22253550 http://dx.doi.org/10.4137/CMO.S7275 |
_version_ | 1782221085644685312 |
---|---|
author | Alegre, Adrian Vicuña, Isabel Aguado, Beatriz |
author_facet | Alegre, Adrian Vicuña, Isabel Aguado, Beatriz |
author_sort | Alegre, Adrian |
collection | PubMed |
description | Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refractory MM (RRMM). Clinical benefit may be greatest when Len+Dex is given at first relapse, and continued treatment appears to provide greater depth of response and improved survival outcomes. The most common adverse events associated with Len+Dex are cytopenias, which are predictable and manageable. Len+Dex is associated with an increased risk of venous thromboembolism, which necessitates adequate prophylaxis. The risk of second primary malignancies does not appear to be increased in patients with RRMM treated with lenalidomide-based therapy. Here we review the safety and efficacy of Len+Dex in RRMM, and provide an overview of data from Spain on the use of Len+Dex in RRMM. |
format | Online Article Text |
id | pubmed-3256976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-32569762012-01-17 Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma Alegre, Adrian Vicuña, Isabel Aguado, Beatriz Clin Med Insights Oncol Review Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refractory MM (RRMM). Clinical benefit may be greatest when Len+Dex is given at first relapse, and continued treatment appears to provide greater depth of response and improved survival outcomes. The most common adverse events associated with Len+Dex are cytopenias, which are predictable and manageable. Len+Dex is associated with an increased risk of venous thromboembolism, which necessitates adequate prophylaxis. The risk of second primary malignancies does not appear to be increased in patients with RRMM treated with lenalidomide-based therapy. Here we review the safety and efficacy of Len+Dex in RRMM, and provide an overview of data from Spain on the use of Len+Dex in RRMM. Libertas Academica 2011-12-06 /pmc/articles/PMC3256976/ /pubmed/22253550 http://dx.doi.org/10.4137/CMO.S7275 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Review Alegre, Adrian Vicuña, Isabel Aguado, Beatriz Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma |
title | Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma |
title_full | Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma |
title_fullStr | Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma |
title_full_unstemmed | Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma |
title_short | Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma |
title_sort | safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256976/ https://www.ncbi.nlm.nih.gov/pubmed/22253550 http://dx.doi.org/10.4137/CMO.S7275 |
work_keys_str_mv | AT alegreadrian safetyandefficacyoflenalidomideinrelapsedorrefractorymultiplemyeloma AT vicunaisabel safetyandefficacyoflenalidomideinrelapsedorrefractorymultiplemyeloma AT aguadobeatriz safetyandefficacyoflenalidomideinrelapsedorrefractorymultiplemyeloma |